1. CD4 and CD8 T lymphocyte interplay in controlling tumor growth
   Dmitrij Ostroumov et al, 2018, Cell. Mol. Life Sci. CrossRef
2. Gene-based Interventions for Cancer Immunotherapy
   Otto L.D. Cerqueira et al, 2018 CrossRef
3. The promise of Immuno-oncology: implications for defining the value of cancer treatment
   Howard L. Kaufman et al, 2019, j. immunotherapy cancer CrossRef
4. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
   Oscar Arrieta et al, 2020, JAMA Oncol CrossRef
5. Older Cancer Patients during the COVID-19 Epidemic: Practice Proposal of the International Geriatric Radiotherapy Group
   Nam P. Nguyen et al, 2020, Cancers CrossRef
6. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice
   Mary K. Nesline et al, 2020, Clinical Therapeutics CrossRef
7. nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
   Corey J. Langer et al, 2021, Front. Oncol. CrossRef
8. Cancer Immunoprevention: Current Status and Future Directions
   Mahsa Keshavarz-Fathi et al, 2021, Arch. Immunol. Ther. Exp. CrossRef
9. Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
   Ke Zhu et al, 2022, Front. Oncol. CrossRef
10. Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review
    Navami Prabhakar Koyande et al, 2022, Vaccines CrossRef
11. Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer
    Alexandros Kalkanis et al, 2022, Diagnostics CrossRef
12. The involvement of Lymphocyte activation gene 3 and the inhibitor in non-small cell lung cancer
    Rongxiang Lin, 2023, HSET CrossRef
13. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
    Ken Kudura et al, 2023, JCM CrossRef
14. CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors
    Fandong Zhu et al, 2023, Cancer Imaging CrossRef
15. Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
    Ashley Jackson et al, 2023, JTO Clinical and Research Reports CrossRef
16. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research
    Raphael Yip et al, 2024, J Immunother Cancer CrossRef
17. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis
    Mohamed Rahouma et al, 2024, Cancers CrossRef
18. The nutrition‐related adverse events associated with immune checkpoint inhibitor treatment for patients with non‐small cell lung cancer: A systematic review
    Kate L. Graham et al, 2024, Nutrition & Dietetics CrossRef
19. Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments
    Fatheia N. Hamza et al, 2024, Pharmaceuticals CrossRef